The $330M Bet That Eyes Are the Next Big Thing in Biotech
A stealth-mode biotech just banked $330 million to take on Roche's $5 billion eye drug, and the CEO helped build the competition. Here's why some of biotech's biggest investors are making their largest bets on eyeballs.
If you told most people that a startup focused on eyeballs just raised $330 million, they'd probably blink twice. But Ollin Biosciences isn't messing around, and neither are its investors.
The Texas-born, now Chicago-headquartered biotech just closed an oversubscribed Series B that ranks as one of the largest biotech Series B rounds in the last two years. The money will fund global Phase 3 trials for a drug that, in early testing, appears to outperform one of the fastest-growing medicines in ophthalmology. And the investor list reads like a who's who of serious biotech capital.
So what's going on here, and why is so much money flowing into eye disease?
A Drug Built to Dethrone a $5 Billion Giant
To understand Ollin's pitch, you need to know about Roche's Vabysmo. Launched in 2022, Vabysmo became a blockbuster almost overnight by targeting two proteins (VEGF and Ang2) that drive the leaky, fragile blood vessels behind conditions like wet age-related macular degeneration and diabetic macular edema. Think of those proteins as co-conspirators: VEGF fuels abnormal blood vessel growth in the retina, while Ang2 makes the vessels unstable, leaky, and inflamed.
Vabysmo was the first drug to block both at once. It raked in roughly $5 billion in 2025 after fewer than four full years on the market.
Ollin's lead candidate, OLN324, goes after the same two targets. But it's engineered to do it better. The molecule is about one-third the size of Vabysmo, which means it can penetrate deeper into retinal tissue. It delivers a higher dose of active antibody per injection. And according to the company, it has roughly 60 times greater potency against Ang2 than Vabysmo does.
In a Phase 1b head-to-head trial called JADE, OLN324 went directly up against Vabysmo in over 150 patients with DME or wet AMD. The early results? OLN324 cleared retinal disease faster and showed superior outcomes. That's the kind of data that makes crossover investors reach for their checkbooks.
Get tomorrow's biotech intelligence before your competitors.
Join thousands of biotech professionals who start their day with our free, daily briefing.
The Money (and Who's Writing the Checks)
The $330 million Series B was co-led by TCGX and ARCH Venture Partners, a founding investor that's been with Ollin since the beginning. But the supporting cast is what really turns heads.
The syndicate includes a16z Bio+Health (Andreessen Horowitz's life sciences arm), Blackstone Multi-Asset Investing, RA Capital Management, Canada Pension Plan Investment Board, accounts advised by T. Rowe Price, sovereign wealth fund Mubadala Capital, and others. When you see pension funds, sovereign wealth, and major crossover investors all piling into the same private round, it usually means one thing: they're underwriting this company for a future IPO.
Ollin hasn't disclosed its valuation, but the composition of that investor list tells its own story. These aren't early-stage gamblers. They're institutions that invest in companies they expect to see on public markets within a few years.
The CEO Who Helped Build the Competition
Here's a fun twist. Ollin's co-founder and CEO, Jason Ehrlich, M.D., Ph.D., previously served as chief medical and development officer at Kodiak Sciences, and before that held leadership roles at Genentech (Roche's biotech division), where he helped support the development of... Vabysmo.
So the person leading the charge to build a better Vabysmo literally helped create the original. That kind of insider knowledge is rare, and investors clearly find it compelling. Ehrlich co-founded Ollin in 2023 with Atul Dandekar, and the company emerged from stealth with a $100 million launch financing backed by ARCH, Mubadala, and Monograph Capital.
In just about three years, Ollin has gone from a stealth startup to a company sitting on $430 million in total funding with Phase 3 trials on deck.
Why Ophthalmology, Why Now?
Eye disease doesn't get the same breathless coverage as oncology or obesity. But the numbers tell a different story. The retina market alone is worth an estimated $18 billion, and it's growing fast as populations age worldwide.
Meanwhile, venture capital in ophthalmology nearly doubled in 2025 compared to 2024, reaching close to $2 billion. The retina sector captured about $1.5 billion of that. And the trend is accelerating: in Q1 2026 alone, ophthalmology biotechs raised roughly $586 million, with $341 million coming from private investors.
The pattern is clear: fewer bets, but much bigger ones. Tenpoint Therapeutics pulled in $235 million for its presbyopia program earlier this year. Aviceda Therapeutics raised $207.5 million for its geographic atrophy candidate in 2025. Ollin's $330 million dwarfs them all.
Investors like ophthalmology for the same reasons drug developers do. The endpoints are well-defined (you can literally measure retinal fluid and visual acuity). The regulatory paths are established. And the commercial benchmarks are obvious: if your drug is demonstrably better than Eylea or Vabysmo, the revenue projections practically write themselves.
The Bigger Picture: A Model Worth Watching
Ollin's story also illustrates a financing model that's gaining momentum. OLN324 was originally developed by Innovent Biologics in China, where it completed early clinical work. Ollin then licensed the asset for global development, assembled a world-class U.S. team, and raised massive capital to run Phase 3 trials.
This "China-origin newco" approach lets companies import clinically validated molecules into Western markets without spending years and hundreds of millions on discovery and early development. It's efficient, and it's attracting serious institutional interest. Trade press has compared Ollin's trajectory to Kailera Therapeutics, which used a similar playbook on its way to a major IPO.
Ollin has already completed an End-of-Phase 2 meeting with the FDA and received scientific advice from the European Medicines Agency on its Phase 3 program. Global Phase 3 trials in both DME and wet AMD are expected to begin in the second half of 2026.
The company also has a second asset, OLN102, a first-in-class bispecific antibody targeting thyroid eye disease and Graves' disease, which is planned to enter clinical development this year.
The Bottom Line
Ollin Biosciences just raised one of the largest private rounds in ophthalmology history, backed by a blue-chip investor syndicate, led by a CEO who literally helped build the drug he's now trying to beat. The early clinical data looks strong. The market is enormous. And the path to Phase 3 (and potentially an IPO) is already mapped out.
In a biotech market still recovering from a brutal downturn, $330 million for an eye disease startup isn't just a vote of confidence in one company. It's a signal that ophthalmology has arrived as a tier-one therapeutic category, right alongside oncology and cardiometabolic disease. The eyes have it.
Clinical & Regulatory4 min read
New Drug Prices Just Dropped for the First Time in Years. Don't Celebrate Yet.
Median launch prices for new drugs dropped more than 40% in 2025, falling to $216,000 from over $370,000 the year before. But before you celebrate, the reason has nothing to do with pharma companies charging less.
